Pharmigene, Inc. (7595.TWO)
TWD 13.8
(0.0%)
TWD 13.8
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -77.53 Million | -23.46 Million | -19.3 Million | -12.77 Million | -23.7 Million |
| Net Income | -72.63 Million | -42.7 Million | -23.77 Million | -9.49 Million | -35.1 Million |
| Depreciation & Amortization | 22.86 Million | 19.76 Million | 15.19 Million | 12.11 Million | 9.61 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | 70 Thousand | - |
| Change in working capital | -35.43 Million | -1.12 Million | -12.82 Million | -17.52 Million | -624 Thousand |
| Other non-cash items | 8.57 Million | -1.33 Million | 2.79 Million | 1.76 Million | 2.4 Million |
| Investing Cash Flow | -657.43 Million | 4.89 Million | -82.28 Million | -73.56 Million | 23.3 Million |
| Investments in PPE | -667.81 Million | -10.58 Million | -18.67 Million | -9.04 Million | -639 Thousand |
| Acquisitions | -21.52 Million | 5.85 Million | -7.8 Million | - | - |
| Investment purchases | -28.93 Million | -2.81 Million | -55.03 Million | -98.01 Million | - |
| Sales/Maturities of investments | 59.73 Million | 16.06 Million | - | 32.84 Million | - |
| Other Investing Activities | 806 Thousand | -4.55 Million | -777 Thousand | -5.37 Million | 23.94 Million |
| Financing Cash Flow | 726.64 Million | -9.18 Million | -6.89 Million | 253.72 Million | -3.07 Million |
| Debt repayment | -559.4 Million | -7.01 Million | -6.89 Million | -6.72 Million | -4.34 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 175 Million | - | - | 259.95 Million | - |
| Other Financing Activities | -557 Thousand | -2.17 Million | - | 500 Thousand | 1.27 Million |
| Accounts receivables | 943 Thousand | -9.18 Million | -2.6 Million | -4.67 Million | 5.73 Million |
| Accounts payables | 758 Thousand | - | - | - | - |
| Inventory | 1.12 Million | -9.86 Million | -7.72 Million | -10.38 Million | -9.6 Million |
| Other working capital | -6.21 Million | 7.27 Million | -1.32 Million | -94 Thousand | 3.24 Million |
| Cash at beginning of period | 76.86 Million | 104.28 Million | 212.77 Million | 45.32 Million | 48.8 Million |
| Cash at end of period | 68.53 Million | 76.86 Million | 104.28 Million | 212.77 Million | 45.32 Million |
| Capital Expenditure | -667.81 Million | -10.58 Million | -18.67 Million | -9.04 Million | -639 Thousand |
| Effect of forex changes on cash | -3000.00 | 319 Thousand | -10 Thousand | 60 Thousand | 3000.00 |
| Net cash flow / Change in cash | -8.32 Million | -27.42 Million | -108.48 Million | 167.44 Million | -3.48 Million |
| Free Cash Flow | -745.34 Million | -34.04 Million | -37.97 Million | -21.81 Million | -24.34 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -24.34 Million | -24.34 Million | -21.98 Million | -72.63 Million | -21.98 Million | -14.33 Million |
| Depreciation & Amortization | 5.65 Million | 5.65 Million | 6.48 Million | 22.86 Million | 6.48 Million | 4.91 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -2.64 Million | -2.64 Million | -4.24 Million | -35.43 Million | -4.24 Million | 2.17 Million |
| Other non-cash items | 2.29 Million | 2.29 Million | -7.24 Million | 8.57 Million | -7.24 Million | -4.52 Million |
| Investing Cash Flow | -3.67 Million | -3.67 Million | -47.29 Million | -657.43 Million | -47.29 Million | -281.42 Million |
| Investments in PPE | -16.08 Million | -16.08 Million | -8.23 Million | -667.81 Million | -8.23 Million | -324.42 Million |
| Acquisitions | - | - | - | -21.52 Million | - | - |
| Investment purchases | -2 Million | - | - | -28.93 Million | - | - |
| Sales/Maturities of investments | 30 Million | - | - | 59.73 Million | - | - |
| Other Investing Activities | 12.41 Million | 12.41 Million | -39.06 Million | 806 Thousand | -39.06 Million | 42.99 Million |
| Financing Cash Flow | 17.23 Million | 17.23 Million | 88.09 Million | 726.64 Million | 88.09 Million | 275.23 Million |
| Debt repayment | -35 Million | - | - | -559.4 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 175 Million | - | - |
| Other Financing Activities | 17.23 Million | 17.23 Million | 88.09 Million | -557 Thousand | 88.09 Million | 275.23 Million |
| Accounts receivables | -86.5 Thousand | -86.5 Thousand | -6.9 Million | 943 Thousand | -6.9 Million | 7.37 Million |
| Accounts payables | -1.35 Million | - | - | - | - | - |
| Inventory | -2.39 Million | -2.39 Million | -1.7 Million | 1.12 Million | -1.7 Million | 2.26 Million |
| Other working capital | -164.5 Thousand | -164.5 Thousand | 4.36 Million | -6.21 Million | 4.36 Million | -7.47 Million |
| Cash at beginning of period | 68.53 Million | - | - | 76.86 Million | 40.96 Million | 58.91 Million |
| Cash at end of period | -5.4 Million | -5.4 Million | 13.78 Million | 68.53 Million | 54.74 Million | 40.96 Million |
| Capital Expenditure | -16.08 Million | -16.08 Million | -8.23 Million | -667.81 Million | -8.23 Million | -324.42 Million |
| Effect of forex changes on cash | 74.5 Thousand | 74.5 Thousand | -26 Thousand | -3000.00 | -26 Thousand | 24.5 Thousand |
| Net cash flow / Change in cash | -73.93 Million | -5.4 Million | 13.78 Million | -8.32 Million | 13.78 Million | -17.94 Million |
| Free Cash Flow | -35.12 Million | -35.12 Million | -35.22 Million | -745.34 Million | -35.22 Million | -336.2 Million |
603929
TPZEF
TNSE
600522
FBRT
2911